Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: Final results of the after-6 protocol 1

Journal of Clinical Oncology

Volumn 27, Issue 28, 2009, Pages 4642-4648

  Pecorelli, Sergio ^a   Favalli, Giuseppe ^a   Gadducci, Angiolo ^a   Katsaros, Dionyssios ^a   Panici, Pierluigi Benedetti ^a   Carpi, Amalia ^a   Scambia, Giovanni ^a   Ballardini, Michela ^a   Nanni, Oriana ^a   Conte, PierFranco ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CORTICOSTEROID; EPIRUBICIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; PACLITAXEL; ANTINEOPLASTIC AGENT; PLATINUM;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART DISEASE; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADOLESCENT; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CHEMISTRY; EPITHELIUM CELL; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPITHELIAL CELLS; FEMALE; HUMANS; LEUKOPENIA; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70350442636     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.9691     Document Type: Article

References (36)

1. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
2. Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699-708, 2000
3. Neijt JP, Engelholm SA, Tuxen MK, et al: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18:3084-3092, 2000
4. Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with sub-optimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 18:106-115, 2000
5. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003
6. du Bois A, Luck HJ, Meier W, et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1329, 2003
7. Gadducci A, Sartori E, Maggino T, et al: Analysis of failures after negative second-look in patients with advanced ovarian cancer: An Italian multicenter study. Gynecol Oncol 68:150-155, 1998
8. Gadducci A, Cosio S, Conte PF, et al: Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: A review of the literature. Crit Rev Oncol Hematol 55:153-166, 2005
9. Heintz AP, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary: FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95:S161-S192, 2006 (suppl 1)
10. Ozols RF: Current controversies in ovarian cancer: Maintenance chemotherapy and neoadjuvant chemotherapy as standard care, in Perry MC (ed): Am Soc Clin Oncol Ed Book 268-275, 2004
11. Bruzzone M, Repetto L, Chiara S, et al: Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecol Oncol 38:392-395, 1990
12. Thomas GM: Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer? Gynecol Oncol 51:97-103, 1993
13. Sorbe B, Swedish- Norwegian Ovarian Cancer Study Group: Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer 13:278-286, 2003
14. Vergote IB, Winderen M, De Vos LN, et al: Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma: Analysis of 313 patients treated primarily or at second-look laparotomy. Cancer 71: 2250-2260, 1993
15. Varia MA, Stehman FB, Bundy BN, et al: Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: A randomized trial of the Gynecologic Oncology Group. J Clin Oncol 21: 2849-2855, 2003
16. Verheijen RH, Massuger LF, Benigno BB, et al: Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal anti-body in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 24:571-578, 2006
17. Piccart MJ, Floquet A, Scarfone G, et al: Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinumbased intravenous chemotherapy. Int J Gynecol Cancer 13:196-203, 2003 (suppl 2)
18. Cure H, Battista C, Guastalla J, et al: Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation therapy for patients (pts) with responsive low-burden advanced ovarian cancer (AOC): Preliminary results of a GINECO/FNCLCC/SFGM-TC study. J Clin Oncol 20:204a, 2001 (suppl; abstr 815)
19. Donato Ml, Aleman A, Champlin RE, et al: Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33:1219-1224, 2004
20. Cure H, Battista C, Guastalla JP, et al: Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/ FNCLCC/SFGM-TC study. J Clin Oncol 23:449, 2004 (suppl; abstr 5006)
21. Hakes TB, Chalas E, Hoskins WJ, et al: Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 45:284-289, 1992
22. Bertelsen K, Jakobsen A, Stroyer J, et al: A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: A Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 49:30-36, 1993
23. Lambert HE, Rustin GJ, Gregory WM, et al: A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma: A North Thames Ovary Group study. Ann Oncol 8:327-333, 1997
24. Bolis G, Danese S, Tateo S, et al: Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: Results from a phase II study. Int J Gynecol Cancer 16:74-78, 2006 (suppl 1)
25. De Placido S, Scambia G, Di Vagno G, et al: Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 22:2635-2642, 2004
26. Pfisterer J, Weber B, Reuss A, et al: Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: A gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98:1036-1045, 2006
27. Hall GD, Brown JM, Coleman RE, et al: Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer 91:621-626, 2004
28. Berek JS, Markman M, Stonebraker B, et al: Intraperitoneal interferon-α in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study. Gynecol Oncol 75:10-14, 1999
29. Berek JS, Taylor PT, Gordon A, et al: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22:3507-3516, 2004
30. Hirte H, Vergote IB, Jeffrey JR, et al: A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 102:300-308, 2006
31. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-2465, 2003
32. Fayers PM, Ashby D, Parmar MKB: Tutorial in biostatistics Bayesian data monitoring in clinical trials. Stat Med 16:1413-1430, 1997
33. Einzig AI, Wiernik PH, Sasloff J, et al: Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748-1753, 1992
34. Markman M, Hakes T, Barakat R, et al: Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: Paclitaxel in refractory ovarian cancer. J Clin Oncol 14:796-799, 1996
35. Zanotti KM, Belinson JL, Kennedy AW, et al: Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol 79:211-215, 2000
36. Markman M, Liu PY, Rothenberg ML, et al: Pretreatment CA125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 24:1454-1458, 2006